Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer

CAR T cells have revolutionised the treatment of haematological malignancies. Despite this, several obstacles still prohibit their widespread use and efficacy. One of these barriers is the use of autologous T cells as the carrier of the CAR. The individual production of CAR T cells results in large...

Full description

Bibliographic Details
Main Authors: Lauren C. Cutmore, John F. Marshall
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/8/1926
_version_ 1797537470857871360
author Lauren C. Cutmore
John F. Marshall
author_facet Lauren C. Cutmore
John F. Marshall
author_sort Lauren C. Cutmore
collection DOAJ
description CAR T cells have revolutionised the treatment of haematological malignancies. Despite this, several obstacles still prohibit their widespread use and efficacy. One of these barriers is the use of autologous T cells as the carrier of the CAR. The individual production of CAR T cells results in large variation in the product, greater wait times for treatment and higher costs. To overcome this several novel approaches have emerged that utilise allogeneic cells, so called “off the shelf” CAR T cells. In this Review, we describe the different approaches that have been used to produce allogeneic CAR T to date, as well as their current pre-clinical and clinical progress.
first_indexed 2024-03-10T12:16:37Z
format Article
id doaj.art-94fb393d9d604702836fad711fcc92fa
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-10T12:16:37Z
publishDate 2021-04-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-94fb393d9d604702836fad711fcc92fa2023-11-21T15:50:28ZengMDPI AGCancers2072-66942021-04-01138192610.3390/cancers13081926Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of CancerLauren C. Cutmore0John F. Marshall1Barts Cancer Institute, Cancer Research UK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, UKBarts Cancer Institute, Cancer Research UK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, UKCAR T cells have revolutionised the treatment of haematological malignancies. Despite this, several obstacles still prohibit their widespread use and efficacy. One of these barriers is the use of autologous T cells as the carrier of the CAR. The individual production of CAR T cells results in large variation in the product, greater wait times for treatment and higher costs. To overcome this several novel approaches have emerged that utilise allogeneic cells, so called “off the shelf” CAR T cells. In this Review, we describe the different approaches that have been used to produce allogeneic CAR T to date, as well as their current pre-clinical and clinical progress.https://www.mdpi.com/2072-6694/13/8/1926CAR T cellimmunotherapyadoptive cell transfer
spellingShingle Lauren C. Cutmore
John F. Marshall
Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
Cancers
CAR T cell
immunotherapy
adoptive cell transfer
title Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
title_full Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
title_fullStr Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
title_full_unstemmed Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
title_short Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
title_sort current perspectives on the use of off the shelf car t nk cells for the treatment of cancer
topic CAR T cell
immunotherapy
adoptive cell transfer
url https://www.mdpi.com/2072-6694/13/8/1926
work_keys_str_mv AT laurenccutmore currentperspectivesontheuseofofftheshelfcartnkcellsforthetreatmentofcancer
AT johnfmarshall currentperspectivesontheuseofofftheshelfcartnkcellsforthetreatmentofcancer